{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00027697", "CSN": null, "TRF": "ORD_1585457_01", "MRN": "33214436", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1292132", "clinicalId": "1293482", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1585457_01", "SampleName": "US1515644.01", "Version": "0", "Sample": {"FM_Id": "ORD_1585457_01", "SampleId": "US1515644.01", "BlockId": "S111-44872B", "TRFNumber": "ORD_1585457_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_03_13", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10067", "MRN": "33214436", "FullName": "\u8521\u79c0\u96c4", "FirstName": "Hsiu Hsiung", "LastName": "Tsai", "SubmittedDiagnosis": "Skin melanoma", "Gender": "Male", "DOB": "1941_04_06", "OrderingMD": "\u9673\u4e09\u5947", "OrderingMDId": "109266", "Pathologist": "\u8449\u5955\u6210", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2022_11_02", "ReceivedDate": "2023-03-31 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Melanoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRAF"}, {"Gene": "KIT"}, {"Gene": "NRAS"}]}, "Summaries": {"alterationCount": "33", "clinicalTrialCount": "13", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ASXL1", "isVUS": "true", "variantName": "R625Q"}, {"geneName": "BCOR", "isVUS": "true", "variantName": "P152L"}, {"geneName": "CCND2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CDK6", "isVUS": "true", "variantName": "R305S"}, {"geneName": "CDKN1B", "isVUS": "true", "variantName": "amplification"}, {"geneName": "EP300", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "E276G"}, {"geneName": "FGF23", "isVUS": "true", "variantName": "amplification"}, {"geneName": "FGF6", "isVUS": "true", "variantName": "amplification"}, {"geneName": "FGFR2", "isVUS": "true", "variantName": "V463D"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "A280T"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "amplification"}, {"geneName": "KRAS", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MKNK1", "isVUS": "true", "variantName": "R35Q"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "K881N"}, {"geneName": "NF1", "isVUS": "true", "variantName": "M1162V"}, {"geneName": "PARP2", "isVUS": "true", "variantName": "A522V"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "amplification"}, {"geneName": "POLE", "isVUS": "true", "variantName": "A2142T"}, {"geneName": "PTPRO", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RAD52", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RET", "isVUS": "true", "variantName": "Q681E"}, {"geneName": "TEK", "isVUS": "true", "variantName": "loss"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "Q61R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "72.44", "isEquivocal": "false", "name": "Q61R"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been reported in up to 2% of cutaneous melanoma samples, but have not been found in uveal melanoma cases (cBioPortal, COSMIC, Feb 2023)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). One study reported KRAS mutations in 4/71 (6%) mucosal melanoma samples (Cosgarea et al., 2017; 28380455). The RAS pathway is a significant driver in melanoma tumorigenesis, although mutations in BRAF and NRAS are more frequently observed than KRAS mutations (Reifenberger et al., 2004; 14961576). In melanoma, high KRAS expression has been reported to be associated with metastasis and with reduced median OS compared with low KRAS expression (Dietrich et al., 2017; 29059159). Mutations in KRAS have also been associated with worse median OS for patients with melanoma brain metastases (Rabbie et al., 2021; 33024263). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). While clinical responses have been reported for patients with KRAS_mutated ovarian (Monk et al., 2020; 32822286, Farley et al., 2013; 23261356, Pejovic et al., 2015; Am J Clin Exp Obstet Gynecol 2:140_143, Slosberg et al., 2018; 29765547, Han et al., 2018; 29946554), cervical small cell neuroendocrine (Lyons et al., 2014; 26075998), or uterine cancer (Slosberg et al., 2018; 29765547) treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS_altered tumors including KRAS_mutated CRC (Tsimberidou et al., 2013; ASCO Abstract e22086, Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733), pancreatic cancer (Van Laethem et al., 2017; 27975152, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), and NSCLC (Blumenschein et al., 2015; 25722381, Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS_mutated (2/2 SDs) or KRAS_amplified (1/1 SD) cancer (Lui et al., 2019; 31118140). Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS_mutated ovarian cancer (Spreafico et al., 2014; ASCO Abstract 5506, Juric et al., 2014; ASCO Abstract 9051, Banerji et al., 2014; ASCO Abstract e13559) and KRAS_mutated endometrioid adenocarcinoma (Shapiro et al., 2019; 31020608). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated low_grade serous ovarian cancer and 12% (2/17) for patients with KRAS_mutated non_small cell lung cancer (NSCLC) in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04985604", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03175432", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT02645149", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT04817956", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).", "Include": "true", "ClinicalTrialNote": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05094336", "Include": "true"}, {"nctId": "NCT05275478", "Include": "true"}, {"nctId": "NCT05245500", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CCND3", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "CCND3 encodes cyclin D3, a G1/S_specific cell cycle regulator. Cyclin D3 interacts with and regulates the cyclin_dependent kinases CDK4 and CDK6, resulting in the phosphorylation and inactivation of Rb and the progression of the cell cycle (Sridhar et al., 2006; 16584130). CCND3 amplification has been associated with increased cyclin D3 expression (Kusugai et al., 2005; 16322284). In the TCGA datasets, CCND3 amplification has been reported in 4% of cutaneous melanoma and 6.3% (5/80) of uveal melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). A study reported cyclin D3 expression has been reported in 96% of primary melanomas, 97% of metastatic melanomas, and 20% of superficial tumors, and association between high cyclin D3 expression and early relapse and decreased overall survival in patients with superficial melanoma tumors (Fl\u00f8renes et al., 2000; 10999753). On the basis of preclinical studies, amplification or activation of CCND3 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib (Gong et al. 2017; 29232554, Tanaka et al., 2020; 31849147) and palbociclib (Schmitz et al., 2012; 22885699, Choi et al., 2012; 23079655, Sawai et al., 2012; 23079656); however, 1 preclinical study implicated CCND3 overexpression as a potential mechanism of resistance to palbociclib (Ketzer et al., 2022; 35013097).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concomitant loss of p16INK4a and p14ARF in melanoma is common, although loss of activity of either may also occur as a result of transcript_specific mutations or hypermethylation (Gallagher et al., 2008; 18953432, Freedberg et al., 2008; 18505964, Bachmann et al., 2004; 15547691, van der Velden et al., 2001; 11431374, Fauri et al., 2011; 22942654, Jonsson et al., 2010; 20703244, Hsieh et al., 2009; 20415670). Homozygous deletion of CDKN2A and/or CDKN2B has been reported in 14_29% of melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, J\u00f6nsson et al., 2010; 20460471, Busch et al., 2010; 20505745, Flores et al., 1996; 8895759). Various correlations between CDKN2A alterations and tumor histology or patient prognosis in melanoma have been reported in the literature, with some studies reporting CDKN2A deletion to be associated with adverse prognosis and other studies reporting no association between CDKN2A deletion and prognosis (Grafstr\u00f6m et al., 2005; 15837753, J\u00f6nsson et al., 2010; 20460471, Puig et al., 2000; 10890376, Busch et al., 2010; 20505745). Studies suggest that deletion of CDKN2A is an early event in melanoma tumorigenesis, and loss of p16INK4a has been associated with increased DNA damage in human benign melanocytic tumors and has been suggested to contribute to tumorigenesis by promoting the proliferation of cells with genetic damage (Fung et al., 2012; 23279822, Matsumura et al., 1998; 9617435). CDKN2A alterations affecting p16INK4a, p14ARF, or both have been strongly associated (up to a 76% risk) with familial melanoma (Aspinwall et al., 2013; 23382133, Bandarchi et al., 2010; 20936153, Binni et al., 2010; 20132244, Garcia_Casado et al., 2009; 19741424, Gruis et al., 1995; 7640518, Harland et al., 2001; 11726555, Liu et al., 1995; 7624155, Puntervoll et al., 2013; 23384855, Ranade et al., 1995; 7647780, Randerson_Moor et al., 2001; 11136714, Veinalde et al., 2013; 23546221). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concomitant loss of p16INK4a and p14ARF in melanoma is common, although loss of activity of either may also occur as a result of transcript_specific mutations or hypermethylation (Gallagher et al., 2008; 18953432, Freedberg et al., 2008; 18505964, Bachmann et al., 2004; 15547691, van der Velden et al., 2001; 11431374, Fauri et al., 2011; 22942654, Jonsson et al., 2010; 20703244, Hsieh et al., 2009; 20415670). Homozygous deletion of CDKN2A and/or CDKN2B has been reported in 14_29% of melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, J\u00f6nsson et al., 2010; 20460471, Busch et al., 2010; 20505745, Flores et al., 1996; 8895759). Various correlations between CDKN2A alterations and tumor histology or patient prognosis in melanoma have been reported in the literature, with some studies reporting CDKN2A deletion to be associated with adverse prognosis and other studies reporting no association between CDKN2A deletion and prognosis (Grafstr\u00f6m et al., 2005; 15837753, J\u00f6nsson et al., 2010; 20460471, Puig et al., 2000; 10890376, Busch et al., 2010; 20505745). Studies suggest that deletion of CDKN2A is an early event in melanoma tumorigenesis, and loss of p16INK4a has been associated with increased DNA damage in human benign melanocytic tumors and has been suggested to contribute to tumorigenesis by promoting the proliferation of cells with genetic damage (Fung et al., 2012; 23279822, Matsumura et al., 1998; 9617435). CDKN2A alterations affecting p16INK4a, p14ARF, or both have been strongly associated (up to a 76% risk) with familial melanoma (Aspinwall et al., 2013; 23382133, Bandarchi et al., 2010; 20936153, Binni et al., 2010; 20132244, Garcia_Casado et al., 2009; 19741424, Gruis et al., 1995; 7640518, Harland et al., 2001; 11726555, Liu et al., 1995; 7624155, Puntervoll et al., 2013; 23384855, Ranade et al., 1995; 7647780, Randerson_Moor et al., 2001; 11136714, Veinalde et al., 2013; 23546221). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "CRKL", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CRKL encodes an adaptor protein that has been shown to mediate growth, motility, and adhesion in solid tumor cells (Yanagi et al., 2012; 22244889). Studies in non_small cell lung cancer (NSCLC) and pancreatic cancer cells have linked CRKL amplification and overexpression with increased cell proliferation and with tumorigenesis (Wang et al., 2012; 22753141, Cheung et al., 2011; 22586683, Kim et al., 2010; 19966867; Fu et al., 2015; 25318601). CRKL amplification has been identified in various solid tumor types, including uterine carcinosarcoma (7%), pancreatic ductal adenocarcinoma (5.5%)(cBio_Witkiewicz et al., 2015; 25855536), lung squamous cell carcinoma (4.5%)(Cancer Genome Atlas Research Network., 2012; 22960745), sarcoma (4%), ovarian serous cystadenocarcinoma (3%), bladder urothelial carcinoma (3%)(Cancer Genome Atlas Research Network., 2014; 24476821), and melanoma (2%)(cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Increased CRKL expression has been reported in many tumor types, including lung (Kim et al., 2010; 19966867, Wang et al., 2012; 22753141), breast (Zhao et al., 2013; 23686806, Singer et al., 2006; 16391854), ovarian (Wang et al., 2011; 21319228, Singer et al., 2006; 16391854), pancreatic (Fu et al., 2015; 25318601), skin (Singer et al., 2006; 16391854), colon (Singer et al., 2006; 16391854, Lan et al., 2014; 24389200), hepatocellular (Liu et al., 2013; 23397142), and gastric cancers (Natsume et al., 2012; 22591714). CRKL overexpression has been shown to significantly correlate with reduced OS for patients with NSCLC or hepatocellular carcinoma (Wang et al., 2012; 22753141, Liu et al., 2013; 23397142) and with tumor size and metastasis for patients with breast cancer (Zhao et al., 2013; 23686806). There are no approved therapies that directly target CRKL (Natsume et al., 2012; 22591714, Cheung et al., 2011; 22586683). Preclinical studies report that some cancer cell lines with CRKL amplification are sensitive to tyrosine kinase inhibitor (TKI) dasatinib (Natsume et al., 2012; 22591714, Lin et al., 2012; 22787428, Cheung et al., 2011; 22586683). However, a patient with CRKL_amplified pancreatic cancer did not respond to dasatinib (Garrido_Laguna et al., 2015; 25897431). CRKL amplification has been shown to be a mechanism of acquired resistance to EGFR TKIs (Suda et al., 2012; 22736441, Cheung et al., 2011; 22586683).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MAPK1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "MAPK1, also known as ERK2, encodes a mitogen_activated protein kinase family member that is involved in the transduction of proliferation and differentiation signals. MAPK1 amplification is associated with increased MAPK1 gene expression (Ercan et al., 2012; 22961667). MAPK1 amplification was detected in one patient with non_small cell lung cancer who exhibited resistance to erlotinib (Ercan et al., 2012; 22961667). Preclinical evidence suggests that amplification of MAPK1 may reduce sensitivity to the third_generation EGFR inhibitor WZ4002 as well as to cytotoxic chemotherapy (Ercan et al., 2012; 22961667). MAPK1 amplification has been reported with the highest incidence in sarcoma (4%), lung squamous cell carcinoma (3%), ovarian serous cystadenocarcinoma (2%), bladder urothelial carcinoma (2%), esophageal squamous cell carcinoma (2%), and testicular germ cell cancer (2%); MAPK1 amplification has been reported in fewer than 1% of hematologic malignancies (cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, MAPK1 amplification has been observed in 7% (5/68) of Type 2 ovarian carcinomas (Rahman et al., 2013; 23820584), 18% (4/22) of laryngeal squamous cell carcinomas (Kostrzewska_Poczekaj et al., 2011; 21896986), and 9% (3/34) of angiosarcoma (Murali et al., 2015; 26440310). MAPK1 amplification is associated with significantly shorter PFS in patients with ovarian cancer (Rahman et al., 2013; 23820584). Further, higher levels of ERK2 or phosphorylated ERK2 expression is a predictor of poor prognosis of acute myelogenous leukemia (Kornblau et al., 2006; 16763210) or angioimmunoblastic T_cell lymphoma (Manso et al., 2017; 26915336). There are no approved drugs that directly target ERK2, although ERK1/2 inhibitors are in clinical trials. In preclinical studies, ERK1/2 inhibitors have been shown to inhibit the activities of ERK2 mutations (Chakraborty et al., 2017; 28512266, Brenan et al., 2016; 27760319, Goetz et al., 2014; 25320010) or restore sensitivity to the EGFR inhibitor WZ4002 in a WZ4002_resistant cell line harboring MAPK1 amplification (Ercan et al., 2012; 22961667).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large_scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1_mutant melanoma samples compared with BRAF_mutant, NRAS_mutant, or BRAF/NRAS/NF1 wild_type samples (Johnson et al., 2016; 27671167). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_1 or anti_PD_L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "VEGFA", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "VEGFA (vascular endothelial growth factor A) encodes a ligand that promotes angiogenesis through the receptor tyrosine kinases VEGFR1 and VEGFR2 (Goel and Mercurio., 2013; 24263190). VEGFA promotes tumor growth by activating both autocrine VEGFR signaling in tumor cells and paracrine signaling to fibroblasts and immune cells in the tumor microenvironment (Goel and Mercurio., 2013; 24263190). VEGFA has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and is associated with response to sorafenib (Horwitz et al., 2014; 24687604). In the TCGA dataset, VEGFA amplification and mutation were observed in 3% and 2% of cutaneous melanoma cases, respectively (cBio_Van Allen et al., 2015; 26359337). VEGFA concentration has been reported as elevated in melanoma (Bauer et al., 2015; 25977583) and uveal melanoma cases (Sahin et al., 2007; 17926107, Missotten et al., 2006; 17030710) and has been correlated with increased tumor size and metastasis (Koch et al., 2014; 24677103, Sahin et al., 2007; 17926107, Missotten et al., 2006; 17030710). The approved VEGFA_targeted agents bevacizumab and ziv_aflibercept have demonstrated efficacy in multiple tumor types; however, expression or amplification of VEGFA has not been established as a reliable biomarker of response to these therapies (Van Cutsem et al., 2012; 22565005, Miles et al., 2013; 23422754, Gianni et al., 2013; 23569311, Cameron et al., 2013; 23932548, Hegde et al., 2013; 23169435, Schneider et al., 2012; 23340303, Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Fountzilas et al., 2011; 21868552, S\u00e1nchez_Rovira et al., 2013; 23397155, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Van Cutsem et al., 2011; EMCC Abstract 803, Xu et al., 2009; 19826039, Hasselbalch et al., 2010; 20666740, Marisi et al., 2017; 28465540, Jubb et al., 2005; 16365183, Goede et al., 2010; 20924372, Bruhn et al., 2013; 24374727, Escudier et al., 2007; 18156031, Yang et al., 2003; 12890841, Burstein et al., 2008; 19047116, Jubb et al., 2011; 21224365, Miles et al., 2017; 27817944, Dowlati et al., 2008; 18316562, Horn et al., 2009; 19826110, Blakeley et al., 2016; 26976425). Preclinical hepatocellular carcinoma (HCC) models with VEGFA amplification showed increased sensitivity to sorafenib, and a small retrospective study reported significantly increased OS for 7 patients with VEGFA_amplified HCC treated with sorafenib (Horwitz et al., 2014; 24687604). However, a prospective biomarker study showed that VEGFA amplification detected by circulating cell_free DNA was not significantly associated with DCR, time to progression, or median OS for patients with HCC treated with first_line sorafenib (Oh et al., 2019; 30935424). It is currently not known if VEGFA amplification predicts response to other inhibitors targeting VEGFRs.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "Q61R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado", "NCTID": "NCT04985604", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases", "StudyPhase": "PHASE 2", "Target": "VEGFA, PD_L1, MEK", "Locations": "Texas", "NCTID": "NCT03175432", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma", "StudyPhase": "PHASE 2", "Target": "ROS1, ALK, MEK, CDK6, CDK4", "Locations": "Wollstonecraft (Australia)", "NCTID": "NCT02645149", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "Improving Public Cancer Care by Implementing Precision Medicine in Norway", "StudyPhase": "PHASE 2", "Target": "PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL", "Locations": "Troms\u00f8 (Norway), Bod\u00f8 (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), F\u00f8rde (Norway), Bergen (Norway)", "NCTID": "NCT04817956", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss", "Title": "AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)_Null Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Tainan (Taiwan), Hong Kong (Hong Kong), Nagoya_shi (Japan), Chuo_ku (Japan), Kashiwa_shi (Japan), Camperdown (Australia), Halle (Saale) (Germany), Salzburg (Austria), Wuerzburg (Germany), Ulm (Germany)", "NCTID": "NCT05094336", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss", "Title": "Safety and Tolerability of TNG908 in Patients With MTAP_deleted Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Lyon (France), Villejuif (France), Missouri, Massachusetts, Tennessee, Texas, Virginia", "NCTID": "NCT05275478", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss", "Title": "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Colorado, Arizona, Minnesota, Massachusetts, New York, Tennessee, Texas, Florida", "NCTID": "NCT05245500", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "1", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "2", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "3", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "4", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "5", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "6", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "7", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "8", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "9", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "10", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "11", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "12", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "13", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "14", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "15", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "16", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "17", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "18", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "19", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "20", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "21", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "22", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "23", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "24", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "25", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "26", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "27", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "28", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "29", "ReferenceId": "33450196", "FullCitation": "Kalev P, et al. Cancer Cell (2021) pmid: 33450196", "Include": "true"}, {"number": "30", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "31", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "32", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "33", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "34", "ReferenceId": "35041419", "FullCitation": "Smith CR, et al. J Med Chem (2022) pmid: 35041419", "Include": "true"}, {"number": "35", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "36", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "37", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "38", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "39", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "40", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "41", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "42", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "43", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "44", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "45", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "46", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "47", "ReferenceId": "35379845", "FullCitation": "Alhalabi O, et al. Nat Commun (2022) pmid: 35379845", "Include": "true"}, {"number": "48", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "49", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "50", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "51", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "52", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "53", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "54", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "55", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "56", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "57", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "58", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "59", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "60", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "61", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "62", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "63", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "64", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "65", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "66", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "67", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "68", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "69", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "70", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "71", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "72", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "73", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "74", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "75", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "76", "ReferenceId": "28380455", "FullCitation": "Cosgarea I, et al. Oncotarget (2017) pmid: 28380455", "Include": "true"}, {"number": "77", "ReferenceId": "14961576", "FullCitation": "Reifenberger J, et al. Int. J. Cancer (2004) pmid: 14961576", "Include": "true"}, {"number": "78", "ReferenceId": "29059159", "FullCitation": "Dietrich P, et al. Oncogene (2018) pmid: 29059159", "Include": "true"}, {"number": "79", "ReferenceId": "33024263", "FullCitation": "Rabbie R, et al. Br J Cancer (2021) pmid: 33024263", "Include": "true"}, {"number": "80", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "81", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "82", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "83", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "84", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "85", "ReferenceId": "32822286", "FullCitation": "Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286", "Include": "true"}, {"number": "86", "ReferenceId": "23261356", "FullCitation": "Farley J, et al. Lancet Oncol. (2013) pmid: 23261356", "Include": "true"}, {"number": "87", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "88", "ReferenceId": "29946554", "FullCitation": "Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554", "Include": "true"}, {"number": "89", "ReferenceId": "26075998", "FullCitation": "Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998", "Include": "true"}, {"number": "90", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "91", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "92", "ReferenceId": "20127139", "FullCitation": "Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139", "Include": "true"}, {"number": "93", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "94", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "95", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "96", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "97", "ReferenceId": "25722381", "FullCitation": "Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381", "Include": "true"}, {"number": "98", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "99", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "100", "ReferenceId": "31020608", "FullCitation": "Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608", "Include": "true"}, {"number": "101", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "102", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "103", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "104", "ReferenceId": "30683722", "FullCitation": "Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722", "Include": "true"}, {"number": "105", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "106", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "107", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "108", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "109", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "110", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "111", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "112", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "113", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "114", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "115", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "116", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "117", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "118", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "119", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "120", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "121", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "122", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "123", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "124", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "125", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "126", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "127", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "128", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "129", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "130", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "131", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "132", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "133", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "134", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "135", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "136", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "137", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "138", "ReferenceId": "18953432", "FullCitation": "Gallagher SJ, et al. Neoplasia (2008) pmid: 18953432", "Include": "true"}, {"number": "139", "ReferenceId": "18505964", "FullCitation": "Freedberg DE, et al. J. Natl. Cancer Inst. (2008) pmid: 18505964", "Include": "true"}, {"number": "140", "ReferenceId": "15547691", "FullCitation": "Bachmann IM, et al. Int. J. Oncol. (2004) pmid: 15547691", "Include": "true"}, {"number": "141", "ReferenceId": "11431374", "FullCitation": "van der Velden PA, et al. Cancer Res. (2001) pmid: 11431374", "Include": "true"}, {"number": "142", "ReferenceId": "22942654", "FullCitation": "Fauri J, et al. Can J Plast Surg (2011) pmid: 22942654", "Include": "true"}, {"number": "143", "ReferenceId": "20703244", "FullCitation": "Jonsson A, et al. J. Invest. Dermatol. (2010) pmid: 20703244", "Include": "true"}, {"number": "144", "ReferenceId": "20415670", "FullCitation": "Hsieh R, et al. Int. J. Dermatol. (2009) pmid: 20415670", "Include": "true"}, {"number": "145", "ReferenceId": "20460471", "FullCitation": "J\u00f6nsson G, et al. Clin. Cancer Res. (2010) pmid: 20460471", "Include": "true"}, {"number": "146", "ReferenceId": "20505745", "FullCitation": "Busch C, et al. J. Invest. Dermatol. (2010) pmid: 20505745", "Include": "true"}, {"number": "147", "ReferenceId": "8895759", "FullCitation": "Flores JF, et al. Cancer Res. (1996) pmid: 8895759", "Include": "true"}, {"number": "148", "ReferenceId": "15837753", "FullCitation": "Grafstr\u00f6m E, et al. Clin. Cancer Res. (2005) pmid: 15837753", "Include": "true"}, {"number": "149", "ReferenceId": "10890376", "FullCitation": "Puig S, et al. Melanoma Res. (2000) pmid: 10890376", "Include": "true"}, {"number": "150", "ReferenceId": "23279822", "FullCitation": "Fung C, et al. Pigment Cell Melanoma Res (2013) pmid: 23279822", "Include": "true"}, {"number": "151", "ReferenceId": "9617435", "FullCitation": "Matsumura Y, et al. Arch. Dermatol. Res. (1998) pmid: 9617435", "Include": "true"}, {"number": "152", "ReferenceId": "23382133", "FullCitation": "Aspinwall LG, et al. Psychooncology (2013) pmid: 23382133", "Include": "true"}, {"number": "153", "ReferenceId": "20936153", "FullCitation": "Bandarchi B, et al. Dermatol Res Pract (2010) pmid: 20936153", "Include": "true"}, {"number": "154", "ReferenceId": "20132244", "FullCitation": "Binni F, et al. Clin. Genet. (2010) pmid: 20132244", "Include": "true"}, {"number": "155", "ReferenceId": "19741424", "FullCitation": "Garcia_Casado Z, et al. Melanoma Res. (2009) pmid: 19741424", "Include": "true"}, {"number": "156", "ReferenceId": "7640518", "FullCitation": "Gruis NA, et al. Melanoma Res. (1995) pmid: 7640518", "Include": "true"}, {"number": "157", "ReferenceId": "11726555", "FullCitation": "Harland M, et al. Hum. Mol. Genet. (2001) pmid: 11726555", "Include": "true"}, {"number": "158", "ReferenceId": "7624155", "FullCitation": "Liu L, et al. Oncogene (1995) pmid: 7624155", "Include": "true"}, {"number": "159", "ReferenceId": "23384855", "FullCitation": "Puntervoll HE, et al. J. Med. Genet. (2013) pmid: 23384855", "Include": "true"}, {"number": "160", "ReferenceId": "7647780", "FullCitation": "Ranade K, et al. Nat. Genet. (1995) pmid: 7647780", "Include": "true"}, {"number": "161", "ReferenceId": "11136714", "FullCitation": "Randerson_Moor JA, et al. Hum. Mol. Genet. (2001) pmid: 11136714", "Include": "true"}, {"number": "162", "ReferenceId": "23546221", "FullCitation": "Veinalde R, et al. Melanoma Res. (2013) pmid: 23546221", "Include": "true"}, {"number": "163", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "164", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "165", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "166", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "167", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "168", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "169", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "170", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "171", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "172", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "173", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "174", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "175", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "176", "ReferenceId": "31700061", "FullCitation": "Su D, et al. Nat Commun (2019) pmid: 31700061", "Include": "true"}, {"number": "177", "ReferenceId": "32923894", "FullCitation": "Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894", "Include": "true"}, {"number": "178", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "179", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "180", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "181", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "182", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "183", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "184", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "185", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "186", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "187", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "188", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "189", "ReferenceId": "16584130", "FullCitation": "Sridhar J, et al. AAPS J (2006) pmid: 16584130", "Include": "true"}, {"number": "190", "ReferenceId": "16322284", "FullCitation": "Kasugai Y, et al. Clin. Cancer Res. (2005) pmid: 16322284", "Include": "true"}, {"number": "191", "ReferenceId": "10999753", "FullCitation": "Fl\u00f8renes VA, et al. Clin. Cancer Res. (2000) pmid: 10999753", "Include": "true"}, {"number": "192", "ReferenceId": "31849147", "FullCitation": "Tanaka Y, et al. Cancer Sci (2020) pmid: 31849147", "Include": "true"}, {"number": "193", "ReferenceId": "22885699", "FullCitation": "Schmitz R, et al. Nature (2012) pmid: 22885699", "Include": "true"}, {"number": "194", "ReferenceId": "23079655", "FullCitation": "Choi YJ, et al. Cancer Cell (2012) pmid: 23079655", "Include": "true"}, {"number": "195", "ReferenceId": "23079656", "FullCitation": "Sawai CM, et al. Cancer Cell (2012) pmid: 23079656", "Include": "true"}, {"number": "196", "ReferenceId": "35013097", "FullCitation": "Ketzer F, et al. Oncogenesis (2022) pmid: 35013097", "Include": "true"}, {"number": "197", "ReferenceId": "22244889", "FullCitation": "Yanagi H, et al. Biochem. Biophys. Res. Commun. (2012) pmid: 22244889", "Include": "true"}, {"number": "198", "ReferenceId": "22753141", "FullCitation": "Wang Y, et al. Mol. Carcinog. (2013) pmid: 22753141", "Include": "true"}, {"number": "199", "ReferenceId": "22586683", "FullCitation": "Cheung HW, et al. Cancer Discov (2011) pmid: 22586683", "Include": "true"}, {"number": "200", "ReferenceId": "19966867", "FullCitation": "Kim YH, et al. Oncogene (2010) pmid: 19966867", "Include": "true"}, {"number": "201", "ReferenceId": "25318601", "FullCitation": "Fu L, et al. Tumour Biol. (2015) pmid: 25318601", "Include": "true"}, {"number": "202", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "203", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "204", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "205", "ReferenceId": "23686806", "FullCitation": "Zhao T, et al. Tumour Biol. (2013) pmid: 23686806", "Include": "true"}, {"number": "206", "ReferenceId": "16391854", "FullCitation": "Singer CF, et al. Oncol. Rep. (2006) pmid: 16391854", "Include": "true"}, {"number": "207", "ReferenceId": "21319228", "FullCitation": "Wang J, et al. Mol. Carcinog. (2011) pmid: 21319228", "Include": "true"}, {"number": "208", "ReferenceId": "24389200", "FullCitation": "Lan B, et al. Front Biosci (Landmark Ed) (2014) pmid: 24389200", "Include": "true"}, {"number": "209", "ReferenceId": "23397142", "FullCitation": "Liu CH, et al. Mol. Cell Proteomics (2013) pmid: 23397142", "Include": "true"}, {"number": "210", "ReferenceId": "22591714", "FullCitation": "Natsume H, et al. J Transl Med (2012) pmid: 22591714", "Include": "true"}, {"number": "211", "ReferenceId": "22787428", "FullCitation": "Lin YC, et al. Neoplasia (2012) pmid: 22787428", "Include": "true"}, {"number": "212", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "213", "ReferenceId": "22736441", "FullCitation": "Suda K, et al. Cancer Metastasis Rev. (2012) pmid: 22736441", "Include": "true"}, {"number": "214", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "215", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "216", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "217", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "218", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "219", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "220", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "221", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "222", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "223", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "224", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "225", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "226", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "227", "ReferenceId": "29320474", "FullCitation": "Eroglu Z, et al. Nature (2018) pmid: 29320474", "Include": "true"}, {"number": "228", "ReferenceId": "27903500", "FullCitation": "Shin DS, et al. Cancer Discov (2017) pmid: 27903500", "Include": "true"}, {"number": "229", "ReferenceId": "29033130", "FullCitation": "Riaz N, et al. Cell (2017) pmid: 29033130", "Include": "true"}, {"number": "230", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "231", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "232", "ReferenceId": "32919529", "FullCitation": "Lancet Oncol. (2020) pmid: 32919529", "Include": "true"}, {"number": "233", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "234", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "235", "ReferenceId": "26343386", "FullCitation": "Shain AH, et al. Nat. Genet. (2015) pmid: 26343386", "Include": "true"}, {"number": "236", "ReferenceId": "26960397", "FullCitation": "Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397", "Include": "true"}, {"number": "237", "ReferenceId": "26559571", "FullCitation": "Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571", "Include": "true"}, {"number": "238", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "239", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "240", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "241", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "242", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "243", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "244", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "245", "ReferenceId": "35355708", "FullCitation": "Ning B, et al. Front Pharmacol (2022) pmid: 35355708", "Include": "true"}, {"number": "246", "ReferenceId": "31515453", "FullCitation": "Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453", "Include": "true"}, {"number": "247", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "248", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "249", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "250", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "251", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "252", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "253", "ReferenceId": "27623135", "FullCitation": "Kube\u010dek O, et al. Melanoma Res. (2016) pmid: 27623135", "Include": "true"}, {"number": "254", "ReferenceId": "27372860", "FullCitation": "Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860", "Include": "true"}, {"number": "255", "ReferenceId": "7561170", "FullCitation": "Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170", "Include": "true"}, {"number": "256", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "257", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "258", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "259", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "260", "ReferenceId": "22961667", "FullCitation": "Ercan D, et al. Cancer Discov (2012) pmid: 22961667", "Include": "true"}, {"number": "261", "ReferenceId": "23820584", "FullCitation": "Rahman MT, et al. Int J Mol Sci (2013) pmid: 23820584", "Include": "true"}, {"number": "262", "ReferenceId": "21896986", "FullCitation": "Kostrzewska_Poczekaj M, et al. Cancer Biomark () pmid: 21896986", "Include": "true"}, {"number": "263", "ReferenceId": "26440310", "FullCitation": "Murali R, et al. Oncotarget (2015) pmid: 26440310", "Include": "true"}, {"number": "264", "ReferenceId": "16763210", "FullCitation": "Kornblau SM, et al. Blood (2006) pmid: 16763210", "Include": "true"}, {"number": "265", "ReferenceId": "26915336", "FullCitation": "Manso R, et al. Br. J. Haematol. (2017) pmid: 26915336", "Include": "true"}, {"number": "266", "ReferenceId": "28512266", "FullCitation": "Chakraborty R, et al. Oncotarget (2017) pmid: 28512266", "Include": "true"}, {"number": "267", "ReferenceId": "27760319", "FullCitation": "Brenan L, et al. Cell Rep (2016) pmid: 27760319", "Include": "true"}, {"number": "268", "ReferenceId": "25320010", "FullCitation": "Goetz EM, et al. Cancer Res. (2014) pmid: 25320010", "Include": "true"}, {"number": "269", "ReferenceId": "24263190", "FullCitation": "Goel HL, et al. Nat. Rev. Cancer (2013) pmid: 24263190", "Include": "true"}, {"number": "270", "ReferenceId": "24687604", "FullCitation": "Horwitz E, et al. Cancer Discov (2014) pmid: 24687604", "Include": "true"}, {"number": "271", "ReferenceId": "26359337", "FullCitation": "Van Allen EM, et al. Science (2015) pmid: 26359337", "Include": "true"}, {"number": "272", "ReferenceId": "25977583", "FullCitation": "Bauer AT, et al. Blood (2015) pmid: 25977583", "Include": "true"}, {"number": "273", "ReferenceId": "17926107", "FullCitation": "Sahin A, et al. Jpn. J. Ophthalmol. () pmid: 17926107", "Include": "true"}, {"number": "274", "ReferenceId": "17030710", "FullCitation": "Missotten GS, et al. Arch. Ophthalmol. (2006) pmid: 17030710", "Include": "true"}, {"number": "275", "ReferenceId": "24677103", "FullCitation": "Koch KR, et al. Invest. Ophthalmol. Vis. Sci. (2014) pmid: 24677103", "Include": "true"}, {"number": "276", "ReferenceId": "22565005", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005", "Include": "true"}, {"number": "277", "ReferenceId": "23422754", "FullCitation": "Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754", "Include": "true"}, {"number": "278", "ReferenceId": "23569311", "FullCitation": "Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311", "Include": "true"}, {"number": "279", "ReferenceId": "23932548", "FullCitation": "Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548", "Include": "true"}, {"number": "280", "ReferenceId": "23169435", "FullCitation": "Hegde PS, et al. Clin. Cancer Res. (2013) pmid: 23169435", "Include": "true"}, {"number": "281", "ReferenceId": "23340303", "FullCitation": "Schneider BP, et al. Clin. Cancer Res. (2013) pmid: 23340303", "Include": "true"}, {"number": "282", "ReferenceId": "26627848", "FullCitation": "Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848", "Include": "true"}, {"number": "283", "ReferenceId": "18182667", "FullCitation": "Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667", "Include": "true"}, {"number": "284", "ReferenceId": "31582283", "FullCitation": "Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283", "Include": "true"}, {"number": "285", "ReferenceId": "20484123", "FullCitation": "Duda DG, et al. Oncologist (2010) pmid: 20484123", "Include": "true"}, {"number": "286", "ReferenceId": "27535973", "FullCitation": "Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973", "Include": "true"}, {"number": "287", "ReferenceId": "26125443", "FullCitation": "Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443", "Include": "true"}, {"number": "288", "ReferenceId": "20008624", "FullCitation": "Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624", "Include": "true"}, {"number": "289", "ReferenceId": "21868552", "FullCitation": "Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552", "Include": "true"}, {"number": "290", "ReferenceId": "23397155", "FullCitation": "S\u00e1nchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155", "Include": "true"}, {"number": "291", "ReferenceId": "24807156", "FullCitation": "Mok T, et al. J Thorac Oncol (2014) pmid: 24807156", "Include": "true"}, {"number": "292", "ReferenceId": "24577128", "FullCitation": "An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128", "Include": "true"}, {"number": "293", "ReferenceId": "29059426", "FullCitation": "Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426", "Include": "true"}, {"number": "294", "ReferenceId": "19826039", "FullCitation": "Xu L, et al. Cancer Res. (2009) pmid: 19826039", "Include": "true"}, {"number": "295", "ReferenceId": "20666740", "FullCitation": "Hasselbalch B, et al. APMIS (2010) pmid: 20666740", "Include": "true"}, {"number": "296", "ReferenceId": "28465540", "FullCitation": "Marisi G, et al. Sci Rep (2017) pmid: 28465540", "Include": "true"}, {"number": "297", "ReferenceId": "16365183", "FullCitation": "Jubb AM, et al. J. Clin. Oncol. (2006) pmid: 16365183", "Include": "true"}, {"number": "298", "ReferenceId": "20924372", "FullCitation": "Goede V, et al. Br. J. Cancer (2010) pmid: 20924372", "Include": "true"}, {"number": "299", "ReferenceId": "24374727", "FullCitation": "Bruhn MA, et al. Int. J. Cancer (2014) pmid: 24374727", "Include": "true"}, {"number": "300", "ReferenceId": "18156031", "FullCitation": "Escudier B, et al. Lancet (2007) pmid: 18156031", "Include": "true"}, {"number": "301", "ReferenceId": "12890841", "FullCitation": "Yang JC, et al. N. Engl. J. Med. (2003) pmid: 12890841", "Include": "true"}, {"number": "302", "ReferenceId": "19047116", "FullCitation": "Burstein HJ, et al. Clin. Cancer Res. (2008) pmid: 19047116", "Include": "true"}, {"number": "303", "ReferenceId": "21224365", "FullCitation": "Jubb AM, et al. Clin. Cancer Res. (2011) pmid: 21224365", "Include": "true"}, {"number": "304", "ReferenceId": "27817944", "FullCitation": "Miles D, et al. Eur. J. Cancer (2017) pmid: 27817944", "Include": "true"}, {"number": "305", "ReferenceId": "18316562", "FullCitation": "Dowlati A, et al. Clin. Cancer Res. (2008) pmid: 18316562", "Include": "true"}, {"number": "306", "ReferenceId": "19826110", "FullCitation": "Horn L, et al. J. Clin. Oncol. (2009) pmid: 19826110", "Include": "true"}, {"number": "307", "ReferenceId": "26976425", "FullCitation": "Blakeley JO, et al. J. Clin. Oncol. (2016) pmid: 26976425", "Include": "true"}, {"number": "308", "ReferenceId": "30935424", "FullCitation": "Oh CR, et al. BMC Cancer (2019) pmid: 30935424", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_03_22 03:15:55", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "813x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SKIN", "disease_ontology": "Skin melanoma", "flowcell_analysis": "2000028219", "gender": "male", "pathology_diagnosis": "C43, Melanoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.20.0", "purity_assessment": "72.0", "specimen": "ORD_1585457_01*US1515644.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1585457_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "833.53", "name": "SQ_US1515644.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.9953", "cds_effect": "455C>T", "depth": "428", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "99.53", "position": "chrX:39934144", "protein_effect": "P152L", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.5", "cds_effect": "827A>G", "depth": "734", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "50.0", "position": "chr2:212587174", "protein_effect": "E276G", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4626", "cds_effect": "1565C>T", "depth": "748", "equivocal": "false", "functional_effect": "missense", "gene": "PARP2", "percent_reads": "46.26", "position": "chr14:20825652", "protein_effect": "A522V", "status": "unknown", "strand": "+", "transcript": "NM_005484", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.3893", "cds_effect": "6424G>A", "depth": "637", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "38.93", "position": "chr12:133202810", "protein_effect": "A2142T", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4629", "cds_effect": "838G>A", "depth": "728", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "46.29", "position": "chr20:57429158", "protein_effect": "A280T", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4003", "cds_effect": "2041C>G", "depth": "652", "equivocal": "false", "functional_effect": "missense", "gene": "RET", "percent_reads": "40.03", "position": "chr10:43610089", "protein_effect": "Q681E", "status": "unknown", "strand": "+", "transcript": "NM_020975", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4883", "cds_effect": "1874G>A", "depth": "940", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "48.83", "position": "chr20:31022389", "protein_effect": "R625Q", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4927", "cds_effect": "2643G>T", "depth": "822", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "49.27", "position": "chr3:49933634", "protein_effect": "K881N", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4316", "cds_effect": "104G>A", "depth": "526", "equivocal": "false", "functional_effect": "missense", "gene": "MKNK1", "percent_reads": "43.16", "position": "chr1:47048932", "protein_effect": "R35Q", "status": "unknown", "strand": "_", "transcript": "NM_003684", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.5126", "cds_effect": "915G>T", "depth": "677", "equivocal": "false", "functional_effect": "missense", "gene": "CDK6", "percent_reads": "51.26", "position": "chr7:92244520", "protein_effect": "R305S", "status": "unknown", "strand": "_", "transcript": "NM_001259", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.7244", "cds_effect": "182A>G", "depth": "1357", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "72.44", "position": "chr12:25380276", "protein_effect": "Q61R", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.5913", "cds_effect": "3484A>G", "depth": "756", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "59.13", "position": "chr17:29559887", "protein_effect": "M1162V", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"allele_fraction": "0.4838", "cds_effect": "1388T>A", "depth": "618", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR2", "percent_reads": "48.38", "position": "chr10:123263355", "protein_effect": "V463D", "status": "unknown", "strand": "_", "transcript": "NM_000141", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "9", "equivocal": "true", "gene": "RAD52", "number_of_exons": "11 of 11", "position": "chr12:1022522_1042247", "ratio": "1.94", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "PTPRO", "number_of_exons": "27 of 27", "position": "chr12:15475633_15747987", "ratio": "1.93", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "PIK3C2G", "number_of_exons": "31 of 31", "position": "chr12:18435015_18800962", "ratio": "1.89", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "FGF23", "number_of_exons": "3 of 3", "position": "chr12:4479508_4488748", "ratio": "1.97", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "TEK", "number_of_exons": "23 of 23", "position": "chr9:27109549_27229257", "ratio": "0.26", "status": "unknown", "type": "loss", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "FGF6", "number_of_exons": "3 of 3", "position": "chr12:4543380_4554736", "ratio": "1.91", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:22002170_22010784", "ratio": "0.28", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "CCND2", "number_of_exons": "5 of 5", "position": "chr12:4383206_4409175", "ratio": "1.87", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "21", "equivocal": "false", "gene": "CRKL", "number_of_exons": "5 of 5", "position": "chr22:21272222_21304133", "ratio": "4.15", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "KDM5A", "number_of_exons": "28 of 28", "position": "chr12:394621_498257", "ratio": "1.95", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "13", "equivocal": "true", "gene": "VEGFA", "number_of_exons": "8 of 8", "position": "chr6:43738443_43752419", "ratio": "2.55", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "KRAS", "number_of_exons": "5 of 5", "position": "chr12:25362722_25398327", "ratio": "1.91", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "EP300", "number_of_exons": "31 of 31", "position": "chr22:41488990_41574960", "ratio": "2.04", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "CDKN1B", "number_of_exons": "3 of 3", "position": "chr12:12870773_12874150", "ratio": "1.89", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "8 of 8", "position": "chr9:21802699_21862058", "ratio": "0.26", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "13", "equivocal": "true", "gene": "CCND3", "number_of_exons": "5 of 5", "position": "chr6:41903677_41909387", "ratio": "2.56", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21968169_21994453", "ratio": "0.27", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "MAPK1", "number_of_exons": "8 of 8", "position": "chr22:22123486_22221735", "ratio": "2.11", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1515644.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.62", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}